Pentoxifylline (Trental), used routinely for the treatment of intermittent claudication, has been shown previously to decrease the levels of tumor necrosis factors-a (TNF-a) RNA in cancer patients and to lead to a general improvement of well being. Increased TNF-a levels have been observed not only in cancer patients but also in cachectic patients with the acquired immunodeficiency syndrome (AIDS), and TNF-a is known to increase the expression of the human immunodeficiency virus type 1 (HIV-1) via activating its long terminal repeat (LTR). Moreover, TNF-a decreases the therapeutic efficacy of zidovudine (AZT). Here we show a significant UMOR NECROSIS FACTOR-a (TNF-a), a cytokine
and in endotoxin-treated human volunteers.* Recently, pentoxifylline-treated cancer patients experienced an improvement in general well being accompanied by significant decreases in TNF-a RNA levels?
TNF-a has been shown to increase human immunodeficiency virus type 1 (HIV-1) expression'"'' via inducing nuclear factors binding to the NF-KB sites in the HIV-1 long terminal repeat (LTR).1Z,13 Antibody to TNF-a suppressed constitutive as well as inducible HIV-1 expression in cultured cells." These observations raise the possibility that a compound capable of blocking TNF-a could decrease HIV-1 expression. Here we show the effects of pentoxifylline on the replication of HIV-1 in human peripheral blood mononuclear cells (PBMC) obtained from normal volunteers and in a human T-cell line, and on the expression of an HIV-1 LTR-linked reporter gene.
MATERIALS AND METHODS
Cells and virus. PBMC, obtained by Ficoll-Hypaque gradient centrifugation of blood from HIV-I-seronegative individuals, were cultured in RPMI-1640 supplemented with 20% fetal calf serum (FCS), penicillin, streptomycin, and L-glutamine. After overnight stimulation with 15 pg/mL of concanavalin A, the cells were maintained in 10 UImL of recombinant interleukin-2 (IL-2; Genzyme, Boston, MA). The monocytoid human cell line U38, derived from U937 cells and containing integrated copies of the HIV-1 LTR ligated to the chloramphenicol acetyl transferase (CAT) gene, was obtained from Dr B. Felber (National Cancer Institute, Frederick, MD). U38 and human Jurkat cells (a CD4+ T-cell line) were grown in RPMI-1640 supplemented with 10% FCS, penicillin, Streptomycin, and L-glutamine. HIV-1 was produced in Jurkat decrease in HIV-1 replication by pentoxifylline in infected human peripheral blood mononuclear cells. The reduction was proportional to the downregulation of expression of a reporter gene, the bacterial gene for chloramphenicol acetyl transferase, linked to the HIV-1 LTR in human monocytoid cells. We conclude that patients with AIDS may benefit from pentoxifylline treatment because of its blockage of TNF-amediated HIV-1 upregulation, from increased efficacy of AZT, and also from improvement in TNF-a-induced cachexia. o 7991 by The American Society of Hematology.
cells. During the log phase of growth, cell-free supernatant was harvested, standardized for reverse transcriptase (RT) activity, 16 and frozen in aliquots at -70°C. Pentoxifylline (a gift from Hoechst-Roussel Pharmaceuticals, Inc, Somerville, NJ) was prepared fresh for each experiment in deionized water and filter sterilized. Chronically HIV-1-infected Jurkat cells were prepared by transfection of the proviral clone pHXBc2" and culture of the transfectants for over 1 year. These cells have a markedly reduced frequency of syncytium formation.
Downregulation of TNF-a by pentoxjjdine in normal human PBMC. PBMC were treated at 37°C for 3 hours with 10 p.gimL LPS with various concentrations of pentoxifylline in RPMI-1640 supplemented as above. Total RNA was extracted according to Chirgwin et al,'* and TNF-a RNA levels were determined by hybridization with a 400-bp TNF-a probe radioactively labeled by random-priming (Boehringer Mannheim, Indianapolis, IN), using standard conditions." The TNF-a probe was generated by polymerase chain reaction (PCR) amplification of a TNF-a cDNA sequence using the oligonucleotides 5'-TTGTAGCAAACCCT-CAAGCT-3' (upstream) and 5'-TGATCCCAAAGTA-GACCTGC-3' (downstream). Filters were washed for 10 minutes at room temperature in 2X SSC (1X SSC, 0.15 mol/L sodium chloride, 0.015 mol/L sodium citrate, pH 7.0), 1% sodium dodecyl sulfate (SDS), followed by 10 minutes at room temperature in 0.5X SSC, 1% SDS, and two washes of 15 minutes each at 65°C in 0.2X SSC, 1% SDS, followed by autoradiography. Appropriate sample loading was verified by rehybridization of stripped filter with a PBMC or Jurkat cells were pretreated with various concentrations of pentoxifylline for 4 hours, after which HIV-1 (lo4 cpm units of RT activity) was added. The cells remained in the appropriate drug concentrations for 7 days. Earlier experiments had shown that high levels of RT could be obtained between days 7 to 10 postinfection in untreated cells, and analysis on day 7 was chosen to ensure a high signal-tonoise ratio. On day 7, cell viability was tested by trypan-blue staining, and RT activity was measured in cell-free supernatants.
Downregulation of gene expression mediated by the H N -I LTR. U38 cells were cultured in the presence or absence of 10 ng/mL phorbol 12-myristate 13-acetate (PMA). Two hours later, the cells were washed once in phosphate-buffered saline (PBS) and cultured in the presence or absence of pentoxifylline. On day 6, cell viability was tested by trypan-blue staining, and CAT activity was measured as described'" after standardizing the cell extracts for protein content.
Inhibition of H N -I replication bypentoxijjJlline.

RESULTS
Pentoxifylline lowered TNF-a RNA levels in LPSsimulated PBMC in a dose-dependent manner (Fig 1) . At concentrations of 100 pmol/L and 500 pmol/L, pentoxifylline decreased TNF-a RNA levels (normalized to p-actin) by 32% and 74%, respectively.
Pentoxifylline decreased the replication of HIV-1 in human PBMC in a dose-dependent fashion (Fig 2) . The therapeutic index, as defined by the ratio of the 50% cell growth inhibitory concentration (LD50) to the 50% virus inhibitory concentration (IC5o), was estimated to be 5. replication as measured by RT activity in tissue culture supernatants was decreased by 25% and 70%, respectively, with little cytotoxicity. A similar level of reduction was obtained by Poli et all5 in experiments with TNF-(w antibodies that decreased the HIV-1 RT activity by 75% in tissue-culture supernatants from PMA-stimulated U1 and ACH-2 cells.
In acutely infected Jurkat cells, a dose-dependent decrease of HIV-1 replication, as measured by RT activity in the supernatant, was noticed in the absence of significant cytotoxicity (Fig 3A) . Because a level of 50% inhibition was not reached, and no cytotoxicity was noted, an estimate for the therapeutic index can not be given. In a pilot study, this decrease in HIV-1 replication was accompanied by a similar decline in TNF-a RNA levels in the same cell populations (data not shown). Untreated Jurkat cells expressed low levels of TNF-a RNA, a finding in agreement with work published earlier." In contrast to acutely infected Jurkat cells, pentoxifylline treatment of chronically HIV-1 infected Jurkat cells was ineffective (Fig 3B) .
Because TNF-a is known to upregulate HIV-1 expres- significant decrease in CAT activity, the extent of which paralleled the inhibition of HIV-1 production seen in the experiments in human PBMC described above (Fig 4) . Because the cytotoxic effects did not reach 50%, an estimate for the therapeutic index can not be given.
DISCUSSION
Our data show that (1) pentoxifylline treatment of acutely infected human PBMC and Jurkat cells decreases HIV-1 replication; (2) in monocytoid U38 cells, HIV-1 LTR-controlled expression of a reporter gene is downregu- For personal use only. on October 3, 2017. by guest www.bloodjournal.org From fever, somnolence, cachexia, and, possibly, nervous system i n j u r i e~.~~~*~ In AIDS patients, the etiology for increased TNF-a may be several fold: HIV-1 infection of mononuclear phagocytes per se can induce TNF-a production, most probably independent of HIV-1 replication. This, in turn, augments HIV-1 replication, resulting in a positive feedback loop. Furthermore, the B-cell population of otherwise asymptomatic HIV-1-seropositive individuals with hypergammaglobulinemia produce higher levels of TNF-a. Lastly, opportunistic infections may lead to increased TNF-a production. Blocking the reciprocal stimulation between TNF-a and HIV-1 replication with pentoxifylline treatment may lead to significant clinical benefits, not only because of the potential lowering of the viral burden, but also by ameliorating TNF-a-induced cachexia and other symptoms. Moreover, TNF-a has been shown to decrease the therapeutic efficacy of zidovudine ( U T ) as well as other nucleoside analoguesz; thus, pentoxifylline may act synergistically with various nucleoside analogues by inhibiting TNF-a production. In conclusion, the clinically approved and widely used pentoxifylline may exert significant benefits for the treatment of HIV-1 infection and its sequelae. Controlled trials will be needed to demonstrate this postulated clinical effectiveness.
